Satsuma Pharmaceuticals, Inc.
SEC CIK 1692830 · STSA · last insider filing 2023-06-12
Directors (from insider filings)
| Name | Capacity as filed | Filings |
|---|---|---|
| RA Capital Healthcare Fund LP | Director | filed 2019 - 2023 |
| RA Capital Management, LLC | Director | filed 2019 - 2023 |
| Kolchinsky Peter | Director | filed 2019 - 2023 |
| King Thomas Braxton | Director | filed 2019 - 2023 |
| Kollins John A | Director · President and CEO | filed 2019 - 2023 |
| Soloway Thomas P | Director | filed 2020 - 2023 |
| Lukatch Heath | Director | filed 2019 - 2023 |
| Shah Rajeev M. | Director | filed 2019 - 2023 |
| Sandoval Elisabeth | Director | filed 2019 - 2023 |
| Takanashi KEN | Director | filed 2019 - 2023 |
| Harsch Mutya | Director | filed 2021 - 2023 |
| Riebe Michael T | Director | filed 2019 - 2023 |
Officers (from insider filings)
| Name | Title as filed | Filings |
|---|---|---|
| O'Neil Thomas P. | Chief Financial Officer | filed 2019 - 2023 |
| Albrecht Detlef | Chief Medical Officer | filed 2019 - 2022 |
About this record
From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.
Source: SEC Insider Transactions Data Sets (Forms 3/4/5), US Federal Government public domain.